Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

or

Watchlist | Portfolio | Dashboard

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS PR Newswire - Mon Dec 12, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia PR Newswire - Mon Dec 5, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates Zacks - Wed Nov 9, 2022

Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis: Q3 Earnings Snapshot AP - Wed Nov 9, 2022

Curis: Q3 Earnings Snapshot

Curis Provides Third Quarter 2022 Business Update PR Newswire - Wed Nov 9, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks - Tue Nov 8, 2022

Agenus (AGEN) delivered earnings and revenue surprises of -5.56% and 14.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis Announces Three Presentations at SITC 2022 PR Newswire - Mon Nov 7, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri Oct 7, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer PR Newswire - Mon Oct 3, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Curis Announces Date for the 2nd Annual VISTA Symposium PR Newswire - Mon Sep 19, 2022

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar